These findings complement a previous report that baseline frequencies of antiinflammatory CD4+CD25+CD127hi T cells at T1D diagnosis are correlated with a favorable response to alefacept (21) and may indicate that response to therapy is linked to the balance of proinflammatory autoreactive cells with this antiinflammatory cell population. Here, CD4 is linked to type 1 diabetes mellitus.